Saved in this browser. Sign in to sync across devices.
Key distinction: Researchers compared documented fragile X diagnoses with expected case counts based on outside prevalence estimates. The difference suggests possible underrecognition; it does not identify or prove that any particular person has an undiagnosed condition.
What did the researchers actually examine?
A research letter published November 6, 2026 in JAMA Network Open analyzed electronic health records for 7,381,668 patients at Atrium Health in Alabama, Georgia, North Carolina and South Carolina. The records spanned 1973–2026. Researchers identified fragile X syndrome (FXS) through diagnosis codes requiring at least two encounters, excluded identified FMR1 premutation carriers, and estimated expected cases from previously published population rates. This was a cross-sectional EHR study, not a genetic screening trial; the authors did not report a participant age range for the overall cohort.
What were the observed numbers?
| Group | Documented diagnoses | Estimated cases | Documented / estimated |
|---|---|---|---|
| All patients in the analysis | 231 | 839 | 27.5% |
| Male patients | 167 | 490 | 34.1% |
| Female patients | 64 | 349 | 18.3% |
| Black female patients | 3 | 85 | 3.5% |
| White female patients | 61 | 264 | 23.1% |
Source: Ghimire et al., Table 1. The Black female subgroup includes just three documented cases, so small-number uncertainty is especially important. The study analyzed records identified as Black or White; it does not establish rates for other populations.
The 27.5% figure is a diagnosis-to-expected-case ratio, not the proportion of people who received genetic testing or a directly measured sensitivity of the healthcare system. Population prevalence, record completeness, access to specialists and how conditions were coded may all affect these figures.
What is fragile X syndrome—and why does an answer matter?
Fragile X syndrome is an inherited condition caused by a change in the FMR1 gene. It can affect learning, development, communication and emotional or behavioral regulation, and may co-occur with autism, ADHD, anxiety or intellectual disability. Presentation is variable, including in girls and women. Having none of the frequently described physical features does not rule it out, and a recognized family history is not required.
A diagnosis can clarify relevant medical and developmental care, connect a family with educational and therapeutic supports, and create an opportunity for genetic counseling. There is currently no cure for fragile X syndrome, but individualized supports and attention to co-occurring needs can improve daily functioning and quality of life. Receiving a diagnosis should not be framed as changing who a person is.
Which genetic test is different from a microarray?
CDC guidance advises healthcare professionals to consider fragile X genetic testing for children with unexplained developmental delay, intellectual disability and/or autism. A standard chromosome test or chromosomal microarray cannot diagnose fragile X syndrome. The CDC identifies a specific FMR1 DNA test as the relevant test. Genetic tests differ in what they detect, so ask which tests have actually been ordered and how results would be interpreted.
This does not mean every autistic person necessarily has fragile X or that one research report makes a genetic test appropriate for every individual. Clinical evaluation, age, personal and family history, previous testing and the person's preferences matter. A genetics professional can discuss what a full mutation, a premutation or an uncertain result means for the person and their relatives.
Genetic evaluation discussion checklist
Use the Print option above to bring this list to a developmental pediatrician, primary-care clinician or genetics appointment.
- What concerns, strengths and everyday support goals should we describe at the visit?
- Given the developmental history or autism diagnosis, would a genetic evaluation help answer useful questions?
- Has an FMR1 DNA test been ordered before? If so, can we review the report—not just a summary?
- Was previous testing a chromosomal microarray or another test that would not detect fragile X?
- Could a genetic counselor explain benefits, limitations, consent, insurance coverage and possible family implications?
- What support can begin or continue without waiting for a genetic diagnosis—communication access, sensory adjustments, education and caregiver support?
- How will we communicate the result and next steps in an accessible, respectful way to the person and their family?
How strong is this finding?
Large observational study; important diagnostic-awareness signal. It used coded records rather than universal FMR1 genetic confirmation. The underlying records cover more than 50 years, healthcare access and testing practices changed over time, and the true population prevalence is uncertain. A clinician may already have considered testing for a given person. The subgroup differences are worth investigating, but the study does not demonstrate the cause of any disparity or prove that a particular screening policy improves health outcomes.
Primary sources and practical support
- Ghimire, Curtin, Downs and Movaghar — JAMA Network Open, published November 6, 2026 (original research) ↗
- CDC — Healthcare providers: five things to know about fragile X (updated April 27, 2026) ↗
- CDC — Fragile X syndrome overview ↗
- Support while waiting for developmental assessment →
- Organize support goals in a private Care Plan →
Editorial status: Source-linked NeuroCoach educational explainer prepared November 7, 2026; independent clinical review pending. Published study and CDC guidance dates are shown separately. No individual diagnosis, genetic-testing order or treatment recommendation is made here.